Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
US11466324B2 · kind B2 · utility
0Cited by
33References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 15, 2019 |
| Grant date | Oct 11, 2022 |
| Priority date | — |
| Expiry date | Jun 8, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/158
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention provides the use of lipocalin 2 (LCN2) as a biomarker for IL-17 mediated diseases and for monitoring the response of a patient to anti-IL-17 therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.